{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:22:51Z","timestamp":1791894171809,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.encep.2012.03.002","type":"journal-article","created":{"date-parts":[[2013,8,5]],"date-time":"2013-08-05T22:17:33Z","timestamp":1375741053000},"page":"86-94","source":"Crossref","is-referenced-by-count":76,"title":["Hyperprolactin\u00e9mies induites par les antipsychotiques\u00a0: physiopathologie, clinique et surveillance"],"prefix":"10.1016","volume":"40","author":[{"given":"I.","family":"Besnard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Auclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Callery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gabriel-Bordenave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Roberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.encep.2012.03.002_bib0005","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia. Mechanism, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.encep.2012.03.002_bib0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hup.1116","article-title":"Hyperpprolactinemia associated with psychotropics - a review","volume":"25","author":"Madhusoodanan","year":"2010","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"10.1016\/j.encep.2012.03.002_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269216307087148","article-title":"Prolactin and dopamine: what is the connection? A review article","volume":"2","author":"Fitzgerald","year":"2008","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.encep.2012.03.002_bib0020","first-page":"147","article-title":"Hyperprolactin\u00e9mies et antipsychotiques","volume":"80","author":"Mestre","year":"2004","journal-title":"Inf Psychiatr"},{"key":"10.1016\/j.encep.2012.03.002_bib0025","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM199505183322008","article-title":"The hypothalamic-pituitary-adrenal axis and immune mediated inflammation","volume":"332","author":"Chrousos","year":"1995","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.encep.2012.03.002_bib0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0269881107087346","article-title":"Antipsychotics and hyperprolactinaemia: clinical recommendations","volume":"22","author":"Pelever","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.encep.2012.03.002_bib0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.encep.2012.03.002_bib0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0165-1781(98)00085-7","article-title":"Change in plasma prolactin and clinical response to haloperidol in schizophrenic and psychoaffective disorder","volume":"81","author":"Chou","year":"1998","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.encep.2012.03.002_bib0045","first-page":"109","article-title":"The effects of antipsychotic-induced hyperprolactinaemia on hypothalamic-pipuitary-gonadal axis","volume":"22","author":"Smith","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.encep.2012.03.002_bib0050","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","article-title":"Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side-effects, and neuroendocrine response","volume":"156","author":"Breier","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2012.03.002_bib0055","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0269881107078281","article-title":"Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with atypical and typical antipsychotics","volume":"21","author":"Busche","year":"2007","journal-title":"J Psychopharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.encep.2012.03.002_bib0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: mechanism and related adverse effects","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinol"},{"key":"10.1016\/j.encep.2012.03.002_bib0065","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4088\/JCP.v63n0506","article-title":"Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone","volume":"63","author":"Kim","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.encep.2012.03.002_bib0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinaemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinol"},{"issue":"Suppl 2","key":"10.1016\/j.encep.2012.03.002_bib0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00128-2","article-title":"Hyperprolactinaemia in response to antipsychotic-drugs: characterization across comparative clinical trials","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinol"},{"issue":"1","key":"10.1016\/j.encep.2012.03.002_bib0080","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pnpbp.2006.07.006","article-title":"Amisulpride-induced hyperprolcatinaemia is reversible following discontinuation","volume":"31","author":"PAparrigopoulos","year":"2007","journal-title":"Prog Neuro Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.encep.2012.03.002_bib0085","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/bmj.324.7332.250","article-title":"Hyperporlactinaemia caused by antipsychotics drugs","volume":"324","author":"Wieck","year":"2002","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.encep.2012.03.002_bib0090","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archpsyc.1976.01770030003001","article-title":"The effect of neuroleptics on serum prolactin in schizophrenic patients","volume":"33","author":"Meltzer","year":"1976","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.encep.2012.03.002_bib0095","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2265.1976.tb01953.x","article-title":"Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups","volume":"5","author":"Rivera","year":"1976","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"10.1016\/j.encep.2012.03.002_bib0100","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/14656566.3.10.1381","article-title":"Antipsychotics: impact on prolactin levels","volume":"3","author":"Goodnick","year":"2002","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.encep.2012.03.002_bib0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000063574","article-title":"Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels","volume":"46","author":"Schlosser","year":"2002","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.encep.2012.03.002_bib0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2006.01.051","article-title":"Partial agonist properties of the antipsychotics SSR 181507, aripiprazole and bifeprunox at dopamine D2\u00a0receptors: G protein activation and prolactin release","volume":"535","author":"Cosi","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"10.1016\/j.encep.2012.03.002_bib0115","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","article-title":"The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia","volume":"22","author":"David","year":"2000","journal-title":"Clin Ther"},{"issue":"2A","key":"10.1016\/j.encep.2012.03.002_bib0120","first-page":"268","article-title":"Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile","volume":"42","author":"Meltzer","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.encep.2012.03.002_bib0125","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v66n0614","article-title":"Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients","volume":"66","author":"Melkersson","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.encep.2012.03.002_bib0130","first-page":"S97","article-title":"Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics","volume":"30","author":"Fric","year":"2003","journal-title":"Psychiatr Prax"},{"key":"10.1016\/j.encep.2012.03.002_bib0135","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-0447.1995.tb09758.x","article-title":"Galactorrhea: subjective response by schizophrenic patients","volume":"91","author":"Wesselmann","year":"1995","journal-title":"Acta Psychiatrica Scand"},{"issue":"Suppl 2","key":"10.1016\/j.encep.2012.03.002_bib0140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0269881107088436","article-title":"Categorical prevalence and severity of hyperproalctinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics","volume":"22","author":"Busche","year":"2008","journal-title":"J Psychopharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.encep.2012.03.002_bib0145","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0269881107088439","article-title":"Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia","volume":"22","author":"O\u2019Keane","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.encep.2012.03.002_bib0150","unstructured":"Soci\u00e9t\u00e9 fran\u00e7aise d\u2019endocrinologie. Diagnostic et prise en charge des hyperprolactin\u00e9mies. Consensus d\u2019experts de la Soci\u00e9t\u00e9 fran\u00e7aise d\u2019endocrinologie. M\u00e9decine clinique endocrinologie & diab\u00e8te 2006:1\u20137. (Hors-s\u00e9rie)."},{"issue":"1","key":"10.1016\/j.encep.2012.03.002_bib0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1210\/jcem-67-1-124","article-title":"Effects of prolactin and estrogen deficiency in amenorrheic bone loss","volume":"67","author":"Klibanski","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.encep.2012.03.002_bib0160","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJM199011013231801","article-title":"Spinal bone loss and ovulatory disturbances","volume":"323","author":"Prior","year":"1990","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.encep.2012.03.002_bib0165","first-page":"692","article-title":"Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea","volume":"75","author":"Biller","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 2","key":"10.1016\/j.encep.2012.03.002_bib0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0306-4530(02)00129-4","article-title":"Hyperprolactinemiaand bone mineral density: the potential impact of antipsychotic agents","volume":"28","author":"Naidoo","year":"2003","journal-title":"Psychoneuroendocrinol"},{"key":"10.1016\/j.encep.2012.03.002_bib0175","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archpsyc.59.12.1147","article-title":"Dopamine antagonists and the development of breast cancer","volume":"59","author":"Wang","year":"2002","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.encep.2012.03.002_bib0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/0269881107082624","article-title":"Adverse effects of prolactin in rodents and humans: breast and prostate cancer","volume":"22","author":"Harvey","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.encep.2012.03.002_bib0185","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1200\/JCO.2006.07.6356","article-title":"A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer","volume":"25","author":"Tworoger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.encep.2012.03.002_bib0190","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0163-7258(98)00017-5","article-title":"Prolactin: the forgotten hormone in breast cancer","volume":"79","author":"Vonderhaar","year":"1998","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.encep.2012.03.002_bib0195","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1158\/0008-5472.CAN-04-1870","article-title":"Plasma prolactin concentrations and risk of postmenopausal breast cancer","volume":"64","author":"Tworoger","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.encep.2012.03.002_bib0200","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1158\/0008-5472.CAN-05-3369","article-title":"Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women","volume":"66","author":"Tworoger","year":"2006","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"10.1016\/j.encep.2012.03.002_bib0205","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0269881107087951","article-title":"Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists","volume":"22","author":"Holt","year":"2008","journal-title":"J Psychopharmacol"},{"issue":"8","key":"10.1016\/j.encep.2012.03.002_bib0210","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4065\/80.8.1050","article-title":"Medication-induced hyperprolactinaemia","volume":"80","author":"Molitch","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.encep.2012.03.002_bib0215","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(81)92334-5","article-title":"Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatments with depot neuroleptics","volume":"317","author":"Wistedt","year":"1981","journal-title":"Lancet"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700612000449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700612000449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T02:11:14Z","timestamp":1715825474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700612000449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0013700612000449"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2012.03.002","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}